Suspension of trading
Biotest AG Share Price Deutsche Boerse AG
Stocks
BIO3
DE0005227235
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
15:46:22 06/06/2025 BST
|
5-day change | 1st Jan Change | ||
| 30.20 EUR | +1.34% |
|
+1.34% | +13.53% |
| 06-15 | Biotest GmbH & Co. KGaA announces Annual dividend, payable on July 24, 2026 | CI |
| 03-25 | Biotest GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 1.31B 1.49B 1.24B 1.13B 2.12B 143B 2.13B 14.87B 5.74B 73.17B 5.61B 5.49B 235B | P/E 2024 * |
-
| P/E 2025 | -17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.06B 2.34B 1.94B 1.76B 3.31B 224B 3.33B 23.27B 8.99B 114B 8.77B 8.58B 368B | EV / Sales 2024 * |
-
| EV / Sales 2025 | 3.36x |
| Free-Float |
19.59% | Yield 2024 * |
-
| Yield 2025 | 0.13% |
| 1 week | +1.34% | ||
| 1 month | +1.34% | ||
| 3 months | +4.50% | ||
| 6 months | +16.15% | ||
| Current year | +13.53% |
| 1 week | 29.6 |  | 30.2 |
| 1 month | 29.6 | | 30.2 |
| 3 years | 23 | | 36.3 |
| 5 years | 19.85 | | 43.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jörg Schüttrumpf
CEO | Chief Executive Officer | 52 | 27/05/2025 |
Oliver Hein
CMP | Compliance Officer | - | 31/12/2016 |
Christian Polus
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 04/05/2022 | |
Dirk Schuck
BRD | Director/Board Member | 48 | 05/04/2022 |
David Ian Bell
BRD | Director/Board Member | 72 | 31/05/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.34% | +1.34% | +14.83% | -15.17% | 1.5B | |
| -0.80% | +14.07% | +678.84% | +96.75% | 79.4B | |
| -4.54% | -5.75% | +34.15% | -9.86% | 78.69B | |
| +2.80% | +3.60% | -6.34% | -27.82% | 59.52B | |
| -0.89% | +2.11% | +7.92% | +170.43% | 46.58B | |
| +2.49% | +0.14% | -8.95% | +33.71% | 46.53B | |
| +0.48% | +4.39% | +65.10% | -11.30% | 33.63B | |
| +0.75% | +0.14% | +48.79% | +112.97% | 25.11B | |
| -3.56% | -0.47% | +3.11% | +135.37% | 22.13B | |
| +0.73% | -1.70% | +61.19% | +100.64% | 15.31B | |
| Average | -0.21% | +4.30% | +89.86% | +58.57% | 45.21B | |
| Weighted average by Cap. | -0.39% | +6.71% | +148.40% | +53.20% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 726M 826M 687M 623M 1.17B 79.26B 1.18B 8.22B 3.18B 40.44B 3.1B 3.03B 130B | 649M 738M 614M 557M 1.05B 70.82B 1.05B 7.35B 2.84B 36.14B 2.77B 2.71B 116B |
| Net income | 26.4M 30.02M 24.96M 22.64M 42.52M 2.88B 42.77M 299M 115M 1.47B 113M 110M 4.72B | -70.7M -80.39M -66.86M -60.64M -114M -7.72B -115M -800M -309M -3.94B -302M -295M -12.65B |
| Net Debt | 552M 628M 522M 474M 890M 60.28B 895M 6.25B 2.42B 30.76B 2.36B 2.31B 98.84B | 742M 843M 701M 636M 1.19B 80.96B 1.2B 8.4B 3.24B 41.31B 3.17B 3.1B 133B |
Employees
-
Sector
Pharmaceuticals
Net sales - Rate of surprise
- Stock Market
- Stocks
- BIO0 Stock
- BIO3 Stock
Select your edition
All financial news and data tailored to specific country editions
